MORE►
Philadelphia
The Peridot Lounge inside Peridot Residences, part of the ongoing adaptive reuse of Dallas’ Santander Tower as office floors are converted into residential space in the city’s urban core. [Photo: Adolfson & Peterson]
Dallas Ranks as a National Leader in Building-to-Apartment Conversions
by Lance Murray | Dec 26, 2025
A RentCafe report finds three major adaptive reuse projects completed last year, including the $40 million office-to-residential conversion inside Dallas’ 50-story Santander Tower that created 291 Peridot Residences apartments downtown. Nearly 3,000 more units are in the city’s redevelopment pipeline, according to the study.
by Lance Murray |
Aug 1, 2023
When a 96-year-old company acquires a 104-year old company, some may think about the past. But Freeman and Sparks see their union as building toward the future—and "the immense potential" the two could share together.
MORE►
by Glenn Hunter |
Jun 30, 2023
Communities Foundation of Texas, which has more than $1 billion in assets and ranks as the seventh-largest foundation in Texas, has named a veteran corporate and nonprofit executive to be its next president and chief executive officer....
MORE►
by Nicole Ward, DRC Data Journalist |
Jun 28, 2023
Organic chemist Lynne Faust is a master at helping companies accelerate drug development at STA Pharmaceuticals, a top-tier contract research and development manufacturer. A move to Weatherford, 25 miles west of Fort Worth, didn't just catalyze her career—it also spurred on her long-time passion for competitive horseback riding, making her life a unique mix of test tubes and trotting.
MORE►
Panna Sharma, CEO of Lantern Pharma
Dallas’ Lantern Pharma Hits Major Milestone on its AI Platform to Advance its Oncology Drug Research and Development
by Alex Edwards | Nov 18, 2020
Lantern Pharma amassed 1 billion data points on its proprietary artificial intelligence platform, which it believes is the most of any company in biotech. Now, the company is able to reduce cost, time, and risk to establish a more sustainable route in oncology drug development.
MORE►
